| Next 10 |
Ad
ENSC News and Press Ensysce Biosciences Inc.
News | Ensysce Biosciences Inc. (NASDAQ:ENSC)
-
2025-04-23 17:13:40 ET More on Ensysce Biosciences Seeking Alpha’s Quant Rating on Ensysce Biosciences Historical earnings data for Ensysce Biosciences Financial information for Ensysce Biosciences Read the full article on Seeking Alpha For fur...
-
2025-04-23 11:26:43 ET DENVER, Colo., Apr 23, 2025 ( 247marketnews.com )- Low-priced stocks with tight floats and compelling catalysts are fueling trader excitement, offering opportunities for quick gains amid volatile markets. Today, 247marketnews.com highlights five NASDAQ stocks to w...
-
2025-04-16 16:40:23 ET More on Ensysce Biosciences Seeking Alpha’s Quant Rating on Ensysce Biosciences Historical earnings data for Ensysce Biosciences Financial information for Ensysce Biosciences Read the full article on Seeking Alpha For fur...
-
~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...
-
2025-03-10 16:40:05 ET More on Ensysce Biosciences Seeking Alpha’s Quant Rating on Ensysce Biosciences Historical earnings data for Ensysce Biosciences Financial information for Ensysce Biosciences Read the full article on Seeking Alpha For fur...
-
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced i...
-
2025-01-11 13:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
~ FDA Breakthrough Therapy designation received for PF614-MPAR ~ ~ PF614-MPAR second clinical trial initiated ~ ~ Lead clinical candidate identified for OUD program ~ ~ PF614 Phase 3 trial poised to commence 1H 2025 ~ SAN DIEGO, CA / ACCESSWIRE / January 8, 2025 / Ensysce Biosci...
-
2024-12-23 08:12:53 ET Ensysce Biosciences ( NASDAQ: ENSC ) said it received notice from the Nasdaq, stating that the company has regained compliance with the minimum bid price requirement. Press Release Read the full article on Seeking Alpha For further deta...
-
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced th...
Stock Information
Get ENSC Alerts
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
6.65% G/L:
$3.29 Last:
907,554 Volume:
$3.09 Open:
$3.29 Close:
Ensysce Biosciences Inc. Website:
Ad
-
2025-04-23 11:26:43 ET DENVER, Colo., Apr 23, 2025 ( 247marketnews.com )- Low-priced stocks with tight floats and compelling catalysts are fueling trader excitement, offering opportunities for quick gains amid volatile markets. Today, 247marketnews.com highlights five NASDAQ stocks to w...
-
~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...
-
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced i...